To ensure the effective involvement of patients, clinical experts and other relevant experts (‘individual experts’) in joint scientific consultation on medicinal products, the HTA secretariat should start their identification as early as possible. Therefore, at the same time as the JSC Subgroup selects medicinal products that are to be subject to joint scientific consultation, the JSC Subgroup should also specify, for each joint scientific consultation, the disease, the therapeutic area concerned and other specific expertise, based on which the HTA secretariat is to identify individual experts to be consulted during that joint scientific consultation. To identify the individual experts, the HTA secretariat should consult the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282, the European reference networks for rare and complex diseases and other relevant sources, agencies and organisations. In making the final selection, the JSC Subgroup should give priority to individual experts who have expertise, across several Member States, in the disease or therapeutic area of the joint scientific consultation.
Recital 9, Regulation (EU) 2024/3169
In forcesince 18 Dec 2024